213 related articles for article (PubMed ID: 33050484)
21. [Anticipated efficacy of HPV vaccination in prophylaxis against nongenital cancers].
Sehnal B; Vojáčková N; Driák D; Kmoníčková E; Vaňousová D; Maxová K; Neumannová H; Sláma J
Klin Onkol; 2014; 27(4):239-46. PubMed ID: 25115712
[TBL] [Abstract][Full Text] [Related]
22. Molecular Approaches Target to Immunotherapy for HPV-Associated Cancers.
Zhang L; Zhou F; Zhao KN
Curr Cancer Drug Targets; 2017; 17(6):512-521. PubMed ID: 27993116
[TBL] [Abstract][Full Text] [Related]
23. [The first vaccine against cancer: the human papillomavirus vaccine].
Bősze P
Orv Hetil; 2013 Apr; 154(16):603-18. PubMed ID: 23587540
[TBL] [Abstract][Full Text] [Related]
24. Review of current knowledge on HPV vaccination: an appendix to the European Guidelines for Quality Assurance in Cervical Cancer Screening.
Arbyn M; Dillner J
J Clin Virol; 2007 Mar; 38(3):189-97. PubMed ID: 17258503
[TBL] [Abstract][Full Text] [Related]
25. HPV genotype distribution in older Danish women undergoing surgery due to cervical cancer.
Hammer A; Mejlgaard E; Gravitt P; Høgdall E; Christiansen P; Steiniche T; Blaakaer J
Acta Obstet Gynecol Scand; 2015 Nov; 94(11):1262-8. PubMed ID: 26300424
[TBL] [Abstract][Full Text] [Related]
26. HPV: Molecular pathways and targets.
Gupta S; Kumar P; Das BC
Curr Probl Cancer; 2018; 42(2):161-174. PubMed ID: 29706467
[TBL] [Abstract][Full Text] [Related]
27. Spotlight on quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine(Gardasil®) in the prevention of premalignant genital lesions, genital cancer, and genital warts in women.
McCormack PL; Joura EA
BioDrugs; 2011 Oct; 25(5):339-43. PubMed ID: 21942919
[TBL] [Abstract][Full Text] [Related]
28. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
Hantz S; Alain S; Denis F
Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
[TBL] [Abstract][Full Text] [Related]
29. Potential impact of a nonavalent HPV vaccine on the occurrence of HPV-related diseases in France.
Riethmuller D; Jacquard AC; Lacau St Guily J; Aubin F; Carcopino X; Pradat P; Dahlab A; Prétet JL
BMC Public Health; 2015 May; 15():453. PubMed ID: 25934423
[TBL] [Abstract][Full Text] [Related]
30. A novel, broad spectrum therapeutic HPV vaccine targeting the E7 proteins of HPV16, 18, 31, 45 and 52 that elicits potent E7-specific CD8T cell immunity and regression of large, established, E7-expressing TC-1 tumors.
Wick DA; Webb JR
Vaccine; 2011 Oct; 29(44):7857-66. PubMed ID: 21816200
[TBL] [Abstract][Full Text] [Related]
31. The IARC commitment to cancer prevention: the example of papillomavirus and cervical cancer.
Franceschi S
Recent Results Cancer Res; 2005; 166():277-97. PubMed ID: 15648196
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of HPV vaccination in the context of high cervical cancer incidence and low screening coverage.
Võrno T; Lutsar K; Uusküla A; Padrik L; Raud T; Reile R; Nahkur O; Kiivet RA
Vaccine; 2017 Nov; 35(46):6329-6335. PubMed ID: 28899625
[TBL] [Abstract][Full Text] [Related]
33. Human papillomavirus disease and vaccines.
Hutchinson DJ; Klein KC
Am J Health Syst Pharm; 2008 Nov; 65(22):2105-12. PubMed ID: 18997137
[TBL] [Abstract][Full Text] [Related]
34. Human papillomavirus vaccine and cervical cancer prevention: practice and policy implications for pharmacists.
McIntosh J; Sturpe DA; Khanna N
J Am Pharm Assoc (2003); 2008; 48(1):e1-13; quiz e14-7. PubMed ID: 18192123
[TBL] [Abstract][Full Text] [Related]
35. Human papillomavirus, cervical cancer, and the vaccines.
Tovar JM; Bazaldua OV; Vargas L; Reile E
Postgrad Med; 2008 Jul; 120(2):79-84. PubMed ID: 18654072
[TBL] [Abstract][Full Text] [Related]
36. Human papillomavirus vaccines: current issues & future.
Kawana K; Yasugi T; Taketani Y
Indian J Med Res; 2009 Sep; 130(3):341-7. PubMed ID: 19901444
[TBL] [Abstract][Full Text] [Related]
37. Changes in Cervical Human Papillomavirus (HPV) Prevalence at a Youth Clinic in Stockholm, Sweden, a Decade After the Introduction of the HPV Vaccine.
Ährlund-Richter A; Cheng L; Hu YOO; Svensson M; Pennhag AAL; Ursu RG; Haeggblom L; Grün N; Ramqvist T; Engstrand L; Dalianis T; Du J
Front Cell Infect Microbiol; 2019; 9():59. PubMed ID: 30949454
[No Abstract] [Full Text] [Related]
38. Can a single dose of human papillomavirus (HPV) vaccine prevent cervical cancer? Early findings from an Indian study.
Sankaranarayanan R; Joshi S; Muwonge R; Esmy PO; Basu P; Prabhu P; Bhatla N; Nene BM; Shaw J; Poli URR; Verma Y; Zomawia E; Pimple S; Tommasino M; Pawlita M; Gheit T; Waterboer T; Sehr P; Pillai MR;
Vaccine; 2018 Aug; 36(32 Pt A):4783-4791. PubMed ID: 29551226
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of the next generation nonavalent human papillomavirus vaccine in the context of primary human papillomavirus screening in Australia: a comparative modelling analysis.
Simms KT; Laprise JF; Smith MA; Lew JB; Caruana M; Brisson M; Canfell K
Lancet Public Health; 2016 Dec; 1(2):e66-e75. PubMed ID: 29253419
[TBL] [Abstract][Full Text] [Related]
40. Overview of the benefits and potential issues of the nonavalent HPV vaccine.
Mariani L; Preti M; Cristoforoni P; Stigliano CM; Perino A
Int J Gynaecol Obstet; 2017 Mar; 136(3):258-265. PubMed ID: 28087890
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]